drugset / Trial / NCT02774382

Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium Difficile Infections

NCT02774382

Phase 3 Unknown 450 enrolled Hvidovre University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate if treatment with fecal microbiota transplantation or rectal bacteriotherapy is superior to standard vancomycin in patients with recurrent Clostridium Difficile infections.

Timeline

Start
2017-05-01
Primary completion
2018-12
Completion
2019-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vancomycin Other / unclassified 125 mg Oral